Sentences with phrase «oncology group study»

The Gynecologic Oncology Group study is sponsored by vaccine developers, Advaxis, Inc., a Princeton, New Jersey - based company that focuses on immunotherapies to combat cancer.

[29] The Radiation Therapy Oncology Group study 0320 evaluated WBRT + stereotactic radiosurgery (SRS) + erlotinib and found significant grade 3 — 5 toxicity rates of 49 %, compared with a rate of 11 % for WBRT alone; the toxicities observed included cytopenias, rash, fatigue, and dehydration, among others.

Combination Chemotherapy and Radiotherapy for Primary Central Nervous System Lymphoma: Radiation Therapy Oncology Group Study 93 — 10

Anti-CD13 Abs in children with extensive chronic GVHD and their relation to soluble CD13 after allogeneic blood and marrow transplantation from a Children's Oncology Groups Study, ASCT0031.

Not exact matches

The study, was reported Feb 13 to the 5th International Conference on Innovative Approaches in Head and Neck Oncology (ICHNO) will reduce significantly the number of HNSCC patients who currently undergo selective neck dissection (SND), a procedure which involves removing a group of lymph nodes from the neck in order to try to eradicate those which may have been reached by the cancer.

The new study is a meta - analysis of three randomized controlled trials conducted by the Alliance for Clinical Trials in Oncology (formerly Cancer and Leukemia Group B)(CALGB) with support from the NCI, Intergroupe Francophone du Myélome (IFM), and the Gruppo Italiano Malattie Ematologiche dell «Adulto (GIMEMA).

A study published in the Journal of Clinical Oncology in January of 2015 led by a Sunnybrook Health Sciences Centre researcher found that the likelihood of dying of other causes for a group of men with low - risk prostate cancer in the study was about nine times higher than the risk of dying from the prostate cancer.

TRINOVA - 2 is evaluating pegylated liposomal doxorubicin in combination with either placebo or trebananib in previously treated patients with ovarian cancer while TRINOVA - 3, also known as ENGOT - Ov2 and Gynecologic Oncology Group — 3001, is studying the use of trebananib in front - line treatment adding it to carboplatin / paclitaxel.

Principal investigator E. Shelley Hwang, M.D., chief of breast surgery at the Duke Cancer Institute and vice chair of research in the Duke University Department of Surgery, will lead the study through the cooperative group, The Alliance for Clinical Trials in Oncology.

In the study, Perlman and colleagues in the Children's Oncology Group and the National Cancer Institute initially identified all genetic mutations in 117 Wilms tumor cases.

A group led by oncologist Pier Guiseppe Pelicci of the European Institute of Oncology in Milan, Italy, had been studying a gene that can make any of three proteins, two of which are activated by growth factors.

This study, conducted by the Gynecologic Oncology Group, a cooperative group funded by the National Cancer Institute, was the second to test bevacizumab under these conditions (first chemotherapy for platinum - sensitive recurrence), a use for which bevacizumab is not currently approved by the Food and Drug AdministraGroup, a cooperative group funded by the National Cancer Institute, was the second to test bevacizumab under these conditions (first chemotherapy for platinum - sensitive recurrence), a use for which bevacizumab is not currently approved by the Food and Drug Administragroup funded by the National Cancer Institute, was the second to test bevacizumab under these conditions (first chemotherapy for platinum - sensitive recurrence), a use for which bevacizumab is not currently approved by the Food and Drug Administration.

The current study, published in the Journal of Clinical Oncology, focused on patients diagnosed at age 35 or younger to better characterize the extent of hereditary CRC in this underrepresented age group.

Professor Sabine Siesling, from the Netherlands Comprehensive Cancer Organisation (IKNL) and University of Twente and Mirelle Lagendijk, MD, from the Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands, and colleagues from other hospitals, studied survival nationwide in nearly 130,000 breast cancer patients, divided into two groups: those diagnosed between 1999 - 2005 and those diagnosed between 2006 - 2012.

Now in the second year of her PhD in Silvio Parodi's experimental oncology group at the National Institute for Cancer Research in Genoa, Stefania Pasa (see photo) was a studious child who often «preferred to... study rather than go out to the cinema.»

The study (known as E3805) was designed by the Eastern Cooperative Oncology Group (ECOG) in 2005.

Women with Stage III ovarian cancer given a combination of intravenous and intraperitoneal chemotherapy following surgical debulking of tumor had a median survival nearly 16 months longer than women who received IV chemotherapy alone, according to a study published conducted by the Gynecologic Oncology Group (GOG), a National Cancer Institute - supported research network, in the January 5, 2006 issue of the New England Journal of Medicine.

The Children's Oncology Group (COG) Supportive Care Guidelines Committee is an inter-professional committee of pediatric hematology / oncology health care professionals which identifies rigorously developed, evidence - based, supportive care guidelines and evaluate them for endorsement by the COG and incorporation into COG study prOncology Group (COG) Supportive Care Guidelines Committee is an inter-professional committee of pediatric hematology / oncology health care professionals which identifies rigorously developed, evidence - based, supportive care guidelines and evaluate them for endorsement by the COG and incorporation into COG study proncology health care professionals which identifies rigorously developed, evidence - based, supportive care guidelines and evaluate them for endorsement by the COG and incorporation into COG study protocols.

In addition to Doñana Biological Station (EBD - CSIC), also taking part in the project were the National Center for Genomic Analysis (CNAG - CRG); the Centre for Genomic Regulation (CRG); the Spanish National Cancer Research Center (CNIO); the Evolutionary Genomics Group of the Hospital del Mar Medical Research Institute (IMIM); the Institute of Evolutionary Biology (IBE, CSIC - UPF); the University Institute of Oncology of Asturias (IUOPA); the Institut de Biotecnologia i de Biomedicina and the Unit of Cell Culture of the Autonomous University of Barcelona (UAB); the Biological Research Center (CIB - CSIC) and the Catalan Institution for Research and Advanced Studies (ICREA).

Two leading international lung cancer organizations, the International Association for the Study of Lung Cancer (IASLC) and British Thoracic Oncology Group (BTOG), are partnering to use the BTOG annual conference, held January 24 - 26, 2018 in Dublin, Ireland, to highlight and inform about changes to the international system of staging lung cancer.

Inclusion Criteria: • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 • Have histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC)(Stage IIIb or greater) • Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 • Known PD - L1 tumor status as determined by an immunohistochemistry (IHC) assay performed by the central laboratory on tissue obtained at Screening • A woman of childbearing potential must have a negative highly sensitive serum (beta - human chorionic gonadotropin [beta - hCG]-RRB- at Screening within 14 days prior to study drug administration Inclusion Criteria for Crossover: • Participants must have been randomized to Arm A of the study and had radiographic disease progression according to RECIST 1.1 • Participants must have a mandatory biopsy at the time of disease progression according to RECIST 1.1 prior to crossing over.

He is a member of the High Risk Neurobalstoma Committee of COG, institutional performance review committee for COG Phase - I consortium and is the Principle Investigator of the Children's Oncology Group, Phase - I, Phase II - III Consortium studies at C.S. Mott Children's Hospital.

Based on our findings, the occurrence of cancer is much higher in adults over 75 years of age compared with the proportion of patients in this age group who enroll in clinical trials,» said lead study author Bindu Kanapuru, MD, medical officer in the Division of Hematology Products, Office of Hematology and Oncology Products in the US Food and Drug Administration's (FDA) Center for Drug Evaluation and Research, who presented the results at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9 — 12 in Atlanta.

Previous research (the Gynecologic Oncology Group's GOG181B trial) has suggested that trastuzumab is inactive in HER2 / neu - expressing endometrial carcinomas, and in the current study, nearly half of the participants «ultimately did not have tumoral HER2 / neu gene amplification,» Dr. Santin said.

At the Children's Oncology Group, we work on the design and implementation of studies regarding Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, and other soft tissue sarcomas.

Together, this translational program is developed within the National Cancer and Cognition Platform (CNO / Ligue Nationale contre le cancer), with the aim to collaborate in a structured way with French oncology groups, research teams as well as pharmaceutical industry, by providing preclinical models and guidance on standard operating procedures for ancillary or future studies in identified population at risk.

Who: Two leading international lung cancer organizations, the International Association for the Study of Lung Cancer (IASLC) and British Thoracic Oncology Group (BTOG), are partnering to use the BTOG annual conference, held January 24 - 26, 2018 in Dublin, Ireland, to highlight and inform about changes to the international system of staging lung cancer.

We are part of a National Cancer Institute - funded Specialized Programs of Research Excellence (SPORE) grant and participate in Children's Oncology Group and internal lymphoma studies within Texas Children's Cancer Center and the Cell and Gene Therapy Program.

From 1980 to 1990, he served as director of the radiation oncology committee of the Pediatric Oncology Group, a U.S. and Canadian collaborative group that studied childhood oncology committee of the Pediatric Oncology Group, a U.S. and Canadian collaborative group that studied childhood Oncology Group, a U.S. and Canadian collaborative group that studied childhood canGroup, a U.S. and Canadian collaborative group that studied childhood cangroup that studied childhood cancers.

We sponsor clinical trials for newly diagnosed neuroblastoma patients through the Children's Oncology Group (COG) and, through COG and the New Approaches to Neuroblastoma Therapy Consortium, Dana - Farber / Boston Children's offers the most Phase I clinical studies in New England for children whose disease has recurred.

Neuroblastoma has specific treatment recommendations developed by the Children's Oncology Group (COG), a nationwide cooperative group devoted to the study and treatment of pediatric malignanGroup (COG), a nationwide cooperative group devoted to the study and treatment of pediatric malignangroup devoted to the study and treatment of pediatric malignancies.

As a direct result of a conversation about my CTR - IN pilot work that I had with a colleague who leads the nursing subcommittee of the Southwest Oncology Group, I was invited to be the nursing coordinator for one of their studies.»

We recently completed a bone marrow transplant study combining MIBG as part of the transplant regimen, and are partnering with both the Children's Oncology Group (COG) and the New Advances in Neuroblastoma Consortium (NANT) to develop new strategies for MIBG therapy.

He served as member of the Experimental Therapeutics - 2 NIH Study Section (1998 - 2003), the NCI Board of Scientific Counselors (1999 - 2004), NCI Parent Subcommittee A for review of Cancer Centers (2004 - 2008), the Breast Core Committee of the Eastern Cooperative Oncology Group (ECOG), and the Board of Directors of the American Association for Cancer Research (2004 - 2007).

We are the only Children's Oncology Group Phase I Consortium member in the state of Michigan, which means that we offer unique studies unavailable at other hospitals in Michigan.

These include studies that are sponsored by the Eastern Cooperative Oncology Group (ECOG), the Gynecologic Oncology Group, the AIDS Malignancy Consortium and Accelerated Clinical Oncology Research Network (ACORN).

The group conducts several clinical studies in the field of interventional oncology to pursue evidences.

In a study performed by the Veterinary Cooperative Oncology Group, this combination treatment resulted in a remission rate of approximately 35 %.

This grant has been used by the Veterinary Cooperative Oncology Group to facilitate the sharing of research results between the universities, clinics and veterinary oncologists who are conducting studies on the prevention and treatment of pet cancer.